Article
Sanofi's Adjuvant Produces a High Immune Response at Low Dose
Author(s):
Sanofi Pasteur (Lyon, France) has produced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.
Sanofi Pasteur (Lyon, France) has produced data showing that its new investigational H5N1 pandemic influenza vaccine containing a proprietary adjuvant achieved a high immune response at the lowest dose of H5N1 antigen reported to date.
The vaccine containing 1.9 micrograms of antigen generated a high level of seroprotective immune response in over 70% of the participants in a clinical trial and, in the same clinical trial, vaccine containing 3.75 micrograms of antigen generated a high level of seroprotective immune response in over 80% of the participants. Further assessment of the vaccine is ongoing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
